LABT

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Today, 8:36 AMLakewood-Amedex reports positive preclinical safety data for Nu-3 gel ahead of Phase 2a trial in infected diabetic foot ulcers

Peers: COAG VBIO AARD ABVE ABVC ABOS ABEO ACET ABVX ABCL

Scroll to Statements

Index	-
Market Cap	4.20M
Enterprise Value	5.95M
Income	-4.23M
Sales	0.00M
Book/sh	-4.04
Cash/sh	0.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Apr 23, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	419.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.02
Current Ratio	0.02
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-8.80
EPS next Y	-
EPS next Q	-0.65
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	17.02% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-100.00%
Sales Y/Y TTM	-
EPS Q/Q	-1900.00%
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	0.00%
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-834.41%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-30.07%
SMA50	-76.01%
SMA200	-83.57%
Trades

Shs Outstand	1.75M
Shs Float	1.75M
Short Float	2.16%
Short Ratio	0.13
Short Interest	0.04M
52W High	98.20 -97.56%
52W Low	2.10 14.24%
Volatility	16.34% 20.89%
ATR (14)	1.22
RSI (14)	17.97
Beta	-
Rel Volume	52.53
Avg Volume	292.30K
Volume	767,795

Perf Week	0.80%
Perf Month	-68.74%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-97.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	12.00
Prev Close	2.55
Price	2.40
Change	-5.92%

Today 08:02AM	Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel (PR Newswire) -5.92%
Jul-07-26 08:02AM	Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance (PR Newswire) -12.77%
Jun-25-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers (PR Newswire) -7.80%
Jun-22-26 08:02AM	Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections (PR Newswire) -5.46%
Jun-16-26 08:02AM	Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum (PR Newswire)
08:02AM	Loading…
May-27-26 08:02AM	Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers (PR Newswire)
May-18-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers (PR Newswire) -36.65%
May-12-26 08:02AM	Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 (PR Newswire)
Apr-28-26 07:33AM	Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors (PR Newswire) +6.28%
Apr-23-26 10:42AM	Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" (PR Newswire)

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

CEODr. Kelvin Cooper Ph.D.

CFO & VP of AdministrationMr. Peter F. Ceccacci

Ph.D.Dr. Thomas Balzer M.D.

Project Manager & Accounting ManagerMs. Tara Endress

Investor RelationsDaniel Kontoh-Boateng

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Lakewood-Amedex Biotherapeutics Inc

Upgrade your Finviz experience